XTL Biopharmaceuticals Ltd. (XTLB) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
XTL Biopharmaceuticals (XTLB) production sites are operating without disruption, ensuring strict adherence to testing schedules. Management's strategy relies on acquiring near-complete biomedical projects to accelerate their time-to-market. This chart illustrates that the asset's market value on GURU.Markets is 0.00. However, the business faces a shortage of recurring revenue, dependence on trial results, and the threat of share devaluation.
xtlbio.com - analytical breakdowns and key metrics (XTLB)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity XTL Biopharmaceuticals|XTLB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital XTL Biopharmaceuticals Ltd.|XTLB - Company Cumulative Debt|Debt to Book Value XTL Bio|XTLB - Company Long-Term Indebtedness|Company Current Liabilities XTL Biopharmaceuticals|Quick Liquidity xtlbio.com
- business earnings and investment ratios data:
XTLB - Company Net Income|Future Profit XTL Biopharmaceuticals|XTLB - Company Value to Net Income|Forward P/E Multiple XTL Biopharmaceuticals|XTLB - Price/Earnings to Growth Ratio|EV/EBITDA Multiple XTL Bio|XTLB - Operating income before deduction of amortization|Earnings per share for the last twelve months XTL Biopharmaceuticals|XTLB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months xtlbio.com|XTLB - Earnings per share trend in current year|Earnings growth forecast for next year XTL Biopharmaceuticals
Initial company analysis:XTL Biopharmaceuticals, Ltd. (XTLB)
For the biotech company XTL Biopharmaceuticals (XTLB), which delegates eco-risks to contractors, calculating business value via the enterprise value to operating profit ratio allows for an assessment of the efficiency of immunological drug development. By analyzing the EV/EBITDA trend of XTL Biopharmaceuticals (XTLB), recorded at 0.00, an investor determines the market revaluation of assets relative to actual cash flow, which is critical for assessing the financial stability of this capital-intensive sector.
Competitor analysis for XTL Biopharmaceuticals
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Corp) - Enterprise Value to Operating Income Before Depreciation|PHVS (Pharvaris N.V.) - Enterprise Value to EBITDA Ratio|ABCL: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|Enterprise Value to EBITDA Ratio PHAR (Pharming)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Immunome - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Gossamer Bio Inc GOSS|KalVista Pharmaceuticals Inc (KALV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Septerna Pharma (SEPN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|savarapharma.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXS (Astria Pharma)|EV/EBITDA Multiple enGene Corp ENGN|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (Aerovate Therapeutics Inc)|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Kyverna Therapeutics Inc.|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|EV/EBITDA Multiple Cabaletta Bio Inc|EV/EBITDA Multiple VTYX|Enterprise Value to EBITDA Ratio theratech.com THTX|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|Eledon Pharmaceuticals Inc. (ELDN) - Company Value to EBITDA|AGEN: Enterprise Value to EBITDA Ratio|CLYM - EV/EBITDA Multiple|ZURA (Zura Bio) - Enterprise Value to EBITDA Ratio|ATYR: Enterprise Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Ikena Oncology, Inc. (IMA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple STTK|Enterprise Value to EBITDA Ratio equilliumbio.com EQ|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|EV/EBITDA Multiple Immunic Therapeutics IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IFRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|X4 Pharma (XFOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CELU|Enterprise Value to Operating Income Before Depreciation INMB (inmunebio.com)|Enterprise Value to EBITDA Ratio BRNS (Barinthus Biotherapeutics plc)|Enterprise Value to Operating Income Before Depreciation Ratio KZR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|Akari Therapeutics, Plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|QTTB: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GeoVax (GOVX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio EDSA (Edesa Biotech Inc)|IBIO (iBio Corp) - EV/EBITDA Multiple|CARM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|Business Value to Operating Income Before Depreciation AIM|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XRTX: EV/EBITDA Multiple|reshapelifesciences.com (HIND) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio REVB|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
